Background Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical ...

Objective: To describe the joint manifestations associated with clonal haematopoiesis and to compare patients with and ...

Objective Interstitial lung disease (ILD) represents the most common and severe organ manifestation observed in patients ...

Objective To investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, ...

Background Disappointing outcomes in Sjögren’s disease (SjD) trials underscore the need for reliable, sensitive endpoints.

Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...

Background Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of ...

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating inflammation assessment. This study aimed to evaluate alternative biomarkers ...

Objectives Ankylosing spondylitis (AS) is the most prevalent form of spondyloarthritis, with a known genetic association with the HLA-B27 molecule. The aim of this study was to assess the contribution ...

Background Treatment of rheumatoid arthritis (RA) with a combination of methotrexate (MTX)+adalimumab (ADA) is more effective than ADA monotherapy. We assessed the toxicity of different doses of MTX ...

Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined ...

Methods Anti-Ku-positive patients were retrieved through four immunology departments. Clusters were derived from unsupervised multiple correspondence analysis, not including the disease’s diagnosis, ...